identifi
risk
factor
understand
patient
risk
develop
ard
significantli
import
abl
develop
prevent
earli
intervent
us
critic
ill
injuri
trial
group
usciit
lung
injuri
prevent
studi
investig
develop
lung
injuri
predict
score
lip
identifi
patient
high
risk
develop
acut
lung
injuri
usciit
research
combin
predispos
condit
eg
highrisk
trauma
highrisk
surgeri
aspir
sepsi
shock
pneumonia
risk
modifi
alcohol
abus
acidosi
tachypnea
greater
creat
score
system
score
system
abl
identifi
patient
risk
develop
ali
use
cutoff
score
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
similarli
increas
use
noninvas
mechan
ventil
clinician
research
wise
recogn
ard
pathophysiolog
may
begin
onset
invas
mechan
ventil
identif
patient
sever
hypoxemia
develop
may
associ
improv
surviv
accordingli
palicc
author
also
note
import
identifi
pediatr
patient
earlier
propos
definit
patient
risk
pard
requir
new
pulmonari
infiltr
chest
radiograph
within
seven
day
known
clinic
insult
supplement
oxygen
requir
deliv
via
invas
noninvas
mechan
meet
oi
osi
criteria
pard
risk
popul
certainli
ongo
futur
target
research
prevent
risk
modif
pard
long
understood
adult
pediatr
patient
preexist
immunodefici
increas
risk
develop
ard
wors
outcom
ard
largest
ard
epidemiolog
studi
adult
lung
safe
patient
ard
identifi
form
immunocompromis
state
patient
proport
infect
etiolog
ard
wors
outcom
includ
higher
icu
hospit
mortal
pediatr
much
earli
data
immunodefici
came
human
immunodefici
viru
hiv
recent
dr
kitchin
colleagu
publish
experi
children
hiv
admit
picu
south
africa
meet
aecc
criteria
author
identifi
high
rate
opportunist
infect
p
jirovecii
cytomegaloviru
overal
mortal
anoth
signific
popul
immun
dysfunct
patient
cancer
immunosuppress
relat
chemotherapi
pediatr
acut
respiratori
distress
syndrom
incid
epidemiolog
studi
pardi
pard
patient
identifi
cancer
immun
suppress
outcom
group
dishearten
mortal
respect
dr
rowan
colleagu
focus
outcom
hematopoiet
stem
cell
transplant
hsct
patient
icu
see
chap
work
shown
hsct
patient
respiratori
failur
often
meet
pard
criteria
first
week
mechan
ventil
diseas
often
sever
longer
ventil
cours
increas
mortal
seem
interest
interplay
ard
bodi
habitu
adult
children
result
nation
health
nutrit
examin
survey
nhane
indic
children
adolesc
unit
state
underweight
overweight
obes
repres
state
malnutrit
known
associ
varieti
comorbid
increas
bmi
shown
independ
associ
increas
risk
ard
develop
underweight
adult
ard
high
rate
mortal
obes
individu
particularli
establish
ard
requir
longer
intens
care
unit
icu
hospit
stay
lo
exhibit
lowest
risk
inhospit
mortal
compar
weight
categori
come
known
obes
paradox
obes
paradox
report
adult
sepsi
ard
obes
individu
exhibit
chronic
inflamm
endotheli
activ
surprisingli
reduc
system
inflammatori
respons
ard
compar
normal
weight
suggest
possibl
protect
attenu
immun
respons
critic
ill
cohort
subject
ward
colleagu
found
pard
patient
obes
obes
paradox
observ
whose
pard
due
system
ill
surprisingli
underweight
exhibit
highest
odd
inhospit
death
acut
onset
often
clear
catastroph
trigger
septic
shock
major
trauma
import
environ
patient
air
qualiti
ard
develop
inappropri
discount
unlik
diseas
process
asthma
chronic
obstruct
pulmonari
diseas
howev
adult
ard
clearli
shown
affect
cigarett
smoke
unreason
think
environment
smoke
exposur
could
affect
pard
adult
ard
popul
dr
calfe
colleagu
demonstr
cigarett
smoke
histori
biomark
smoke
exposur
methylnitrosamino
associ
develop
ard
patient
sepsi
impair
fluid
clearanc
epitheli
endotheli
effect
immun
modul
could
underli
effect
alli
studi
reilli
colleagu
studi
critic
ill
adult
trauma
patient
conjunct
air
qualiti
metric
week
prior
present
interestingli
nitrogen
dioxid
sulfur
dioxid
particul
matter
micromet
week
significantli
associ
ard
develop
investig
pard
may
reveal
predispos
environment
factor
includ
environment
smoke
exposur
ambient
air
pollut
risk
factor
develop
seriou
pard
well
known
immun
system
develop
assum
complex
age
children
repres
heterogen
patient
popul
compar
adult
regard
predispos
condit
etiolog
respons
therapi
exact
impact
age
risk
develop
ard
sever
ard
remain
incomplet
elucid
nonetheless
epidemiolog
studi
date
consist
endors
differenti
pard
outcom
base
age
suggest
increas
risk
older
age
studi
suggest
associ
age
pard
outcom
similarli
studi
also
show
differenti
risk
wors
clinic
outcom
either
male
femal
gender
similarli
risk
factor
outcom
ard
patient
differ
racial
ethnic
background
also
incomplet
investig
adult
studi
suggest
increas
risk
death
african
american
hispan
ard
cohort
differenti
respons
treatment
determin
post
hoc
nihfund
fluid
cathet
treatment
trial
pediatr
studi
pard
patient
like
limit
studi
size
consist
observ
increas
risk
within
racial
ethnic
group
either
pardi
studi
result
indic
increas
risk
death
across
differ
racial
group
mortal
significantli
higher
hispan
cohort
compar
nonhispan
patient
ethnic
p
final
studi
address
racial
ethnic
impact
risk
develop
ard
pard
may
entir
differ
risk
profil
may
better
studi
genet
risk
perspect
exampl
dahmer
colleagu
determin
genet
polymorph
gene
factor
involv
splice
cystic
fibrosi
transmembran
regul
conduct
associ
increas
risk
pneumoniaassoci
pard
develop
african
american
nonhispan
caucasian
children
area
like
complet
examin
year
come
investig
focus
genet
contribut
pard
develop
inher
fraught
challeng
includ
limit
wide
array
diseas
state
associ
pard
develop
b
pard
diagnosi
definit
syndrom
rather
clearli
defin
entiti
proven
diagnost
confirmatori
test
c
larg
number
patient
requir
complet
genom
studi
adequ
power
said
genom
approach
offer
promis
opportun
identifi
novel
mechanist
pathway
diseas
may
offer
pharmacolog
therapeut
target
futur
certainli
latent
class
analyt
strategi
identifi
subphenotyp
ard
patient
differenti
risk
respons
therapi
distinct
clinic
outcom
investig
genet
variant
may
offer
area
common
biolog
within
subphenotyp
may
identifi
previous
unidentifi
subphenotyp
date
although
multipl
singlenucleotid
polymorph
snp
identifi
associ
ard
risk
almost
studi
done
adult
surprisingli
reproduc
problemat
notabl
function
variant
identifi
date
variant
encod
angiotensinconvert
enzym
ace
surfact
protein
b
sftpb
potenti
pharmacolog
target
snp
identifi
date
receptor
antagonist
confirm
function
signific
dysregul
coagul
contribut
wors
outcom
ard
genet
studi
patient
enrol
adult
ardsnet
fluid
cathet
treatment
trial
report
genet
variant
thrombomodulin
endotheli
protein
c
receptor
gene
independ
associ
mortal
independ
treatment
trial
alloc
find
code
variant
associ
decreas
risk
ard
adult
support
understand
pathway
cytokin
causal
implic
ard
risk
howev
studi
children
acut
respiratori
failur
dahmer
colleagu
unabl
identifi
genet
variant
pathway
gene
associ
pard
initi
nhlbi
host
exom
sequenc
project
includ
investig
snp
exom
adult
ard
healthi
control
project
regulatori
gene
arylsulfatas
asrd
identifi
present
adult
ard
control
protein
code
gene
xk
kell
blood
group
complex
member
present
minor
allel
frequenc
ard
patient
control
certain
come
although
mani
investig
current
underway
far
fewer
public
exist
genet
associ
establish
pard
patient
patient
risk
pard
wei
colleagu
identifi
linkag
disequilibrium
differ
allel
genotyp
frequenc
nitric
oxid
synthesi
polymorph
measur
pard
patient
comparison
healthi
control
mention
earlier
perezmarquez
dahmer
colleagu
determin
potenti
racial
ethnic
contribut
pard
develop
pediatr
patient
communityacquir
pneumonia
specif
group
identifi
variant
cystic
fibrosi
transmembran
conduct
regul
cftr
splice
factor
gene
independ
associ
pard
african
american
children
without
cystic
fibrosi
pard
secondari
communityacquir
pneumonia
addit
variant
identifi
nonhispan
caucasian
children
also
without
cystic
fibrosi
associ
increas
risk
pard
develop
cftr
chlorid
channel
alveolar
epitheli
cell
long
understood
integr
mainten
fluid
homeostasi
lung
impair
ard
alveolar
epitheli
cell
injuri
propag
surprisingli
research
complet
risk
factor
associ
develop
ard
adult
compar
pediatr
popul
diagnos
commonli
associ
adult
ard
includ
pneumonia
extrapulmonari
sepsi
aspir
noncardiogen
shock
trauma
understand
associ
ard
develop
ingrain
recent
studi
indic
clinician
may
miss
ard
diagnos
patient
present
known
risk
factor
one
frequent
assumpt
ard
pediatr
patient
often
relat
direct
lung
injuri
seen
adult
test
consider
compar
epidemiolog
adult
ard
pard
len
two
larg
intern
cohort
studi
adult
larg
observ
studi
understand
global
impact
sever
respiratori
failur
lung
safe
investig
recruit
sampl
patient
icu
identifi
patient
ard
use
berlin
definit
patient
pneumonia
risk
factor
ard
follow
extrapulmonari
sepsi
aspir
noncardiogen
shock
trauma
risk
factor
identifi
patient
pediatr
pardi
studi
intern
point
preval
studi
survey
picu
admiss
patient
requir
mechan
ventil
patient
identifi
pard
base
palicc
criteria
among
pard
patient
common
risk
factor
pneumonia
lower
respiratori
tract
infect
distantli
follow
sepsi
aspir
trauma
drown
nonsept
shock
therefor
although
berlin
palicc
definit
ard
differ
result
two
larg
epidemiolog
studi
strongli
indic
etiolog
pard
ard
may
dispar
sometim
assum
descript
ard
pard
break
etiolog
direct
indirect
caus
pediatr
acut
critic
care
medicin
asian
network
paccman
publish
studi
compar
pulmonari
versu
extrapulmonari
ard
extrapulmonari
group
includ
patient
sepsi
massiv
transfus
burn
multitrauma
hemorrhag
shock
compris
patient
pard
cohort
extrapulmonari
group
higher
mortal
higher
proport
multipl
organ
dysfunct
higher
median
oxygen
index
similar
studi
adult
examin
patient
ard
aecc
criteria
direct
ard
defin
pneumonia
aspir
indirect
ard
defin
nonpulmonari
sepsi
pancreat
author
show
similar
mortal
direct
vs
indirect
two
group
direct
group
higher
lung
injuri
score
vs
indirect
group
organ
dysfunct
median
vs
organ
system
primari
pulmonari
infect
common
caus
pard
pardi
studi
underli
twothird
case
pard
identifi
direct
pard
case
lower
mortal
indirect
caus
like
sepsi
nonsept
shock
primari
pulmonari
infect
lead
ard
relat
viral
etiolog
bacteri
etiolog
case
influenza
lead
staphylococcu
aureu
infect
much
attent
paid
pandem
virus
lead
drastic
increas
ard
patient
influenza
includ
middl
eastern
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
coronaviru
interestingli
extrem
virul
coronaviru
infect
thought
immun
mediat
earli
exagger
activ
complement
cascad
commonli
viral
etiolog
caus
upper
respiratori
infect
bronchiol
case
commonli
encount
pediatr
intens
care
unit
respiratori
syncyti
viru
rsv
adenoviru
rhinoviru
human
metapneumoviru
similarli
bacteri
caus
pard
often
common
pathogen
caus
communityacquir
pneumonia
includ
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
expect
immunosuppress
also
place
patient
greater
risk
fungal
parasit
caus
ard
includ
pneumocysti
jirovecii
patient
retain
higher
mortal
regardless
ard
sever
final
palicc
definit
also
allow
patient
chronic
lung
diseas
diagnos
pard
may
see
increas
pathogen
specif
technologydepend
chronic
ventil
patient
import
pard
etiolog
soon
aspir
identifi
third
common
etiolog
pard
pardi
studi
underli
incid
seen
aspir
commonli
thought
aspir
stomach
content
also
aspir
household
chemic
blood
substanc
swallow
dysfunct
alter
conscious
place
patient
risk
inhal
pharyng
content
acid
stomach
content
lead
direct
pulmonari
epitheli
damag
neutrophil
inflamm
commonli
describ
chemic
pneumon
bacteria
digest
tract
also
caus
secondari
aspir
pneumonia
develop
ard
follow
trauma
multifactori
differ
mechan
lead
ard
result
direct
thorac
trauma
includ
pulmonari
contus
secondari
inflamm
infect
develop
major
trauma
pathophysiolog
traumainduc
ard
also
seem
differ
etiolog
biomark
includ
von
willebrand
factor
antigen
intercellular
adhes
surfact
proteind
found
lower
trauma
patient
process
lead
ard
interestingli
lung
safe
pardi
studi
describ
similar
preval
trauma
incit
factor
ard
sever
studi
use
nation
trauma
databank
ntdb
evalu
epidemiolog
pediatr
traumainduc
ard
killien
colleagu
examin
children
year
old
admit
level
ii
adult
pediatr
trauma
center
ard
incid
pediatr
trauma
patient
mechan
ventil
trauma
patient
injuri
sever
score
iss
strong
risk
factor
ard
overal
injuri
sever
predict
outcom
chest
trauma
alon
author
also
identifi
patient
went
develop
ard
normal
glasgow
coma
scale
gc
respiratori
rate
arriv
emerg
depart
ed
mortal
patient
develop
ard
dr
killien
studi
motor
vehicl
crash
common
mechan
among
ard
anoth
studi
use
ntdb
de
roulet
colleagu
demonstr
young
children
nonaccident
injuri
near
drown
independ
associ
develop
ard
follow
respiratori
infect
sepsi
next
common
etiolog
pard
endotheli
activ
cytokinemedi
inflamm
reactiv
oxygen
speci
disrupt
normal
coagul
cascad
present
patient
sever
sepsi
lead
develop
diffus
alveolar
damag
given
inflamm
sepsi
thought
trigger
inflamm
cell
damag
ard
studi
attempt
target
group
specif
antiinflammatori
therapi
detail
discuss
sepsi
beyond
scope
chapter
investig
pathophysiolog
common
pathway
diseas
lead
therapeut
target
transfus
blood
product
uncommon
signific
caus
acut
lung
injuri
ard
consensu
definit
transfusionrel
acut
lung
injuri
trali
mirror
aecc
berlin
definit
ard
except
lung
injuri
subsequ
ard
develop
within
hour
transfus
trali
may
consid
twohit
phenomenon
first
hit
patient
diseas
process
second
hit
neutrophil
activ
capillari
leak
adult
pediatr
investig
confirm
transfus
multipl
blood
product
particularli
proteinrich
fresh
frozen
plasma
platelet
associ
develop
ard
trali
unfavor
outcom
ard
includ
greater
mortal
diseas
process
result
system
inflammatori
respons
place
patient
risk
ard
one
classic
exampl
lung
injuri
develop
acut
pancreat
also
note
ashbaugh
et
al
inflammatori
cytokin
chemokin
releas
result
vascular
endotheli
alveolar
epitheli
damag
potenti
exacerb
pancreat
enzym
compromis
intestin
barrier
common
pathway
vascular
permeabl
fluid
leak
often
underli
ard
follow
anoth
common
mechan
system
inflamm
ischemia
reperfus
occur
cardiopulmonari
bypass
congenit
heart
defect
surgic
repair
lead
multipl
organ
dysfunct
syndrom
mod
includ
ard
howev
outcom
significantli
better
mod
bypass
form
among
etiolog
ard
perhap
interest
potenti
meaning
area
focu
potenti
modifi
area
care
deliv
patient
acut
respiratori
failur
method
respiratori
support
medic
health
care
deliveri
potenti
target
prevent
develop
ard
atrisk
patient
larg
studi
practic
ventil
critic
ill
adult
without
ard
onset
ventil
provent
studi
group
attempt
identifi
factor
intern
multicent
cohort
studi
identifi
patient
undergo
mechan
ventil
risk
ard
defin
lung
injuri
prevent
score
higher
ventil
variabl
tidal
volum
peep
drive
pressur
associ
develop
ard
risk
risk
interestingli
higher
patient
develop
ard
note
limit
studi
well
effort
prevent
ard
larg
number
patient
ard
time
intub
raymondo
colleagu
test
whether
outcom
differ
ard
patient
manag
german
univers
nonunivers
hospit
found
surviv
benefit
patient
treat
univers
hospit
differ
seen
use
higher
lower
peep
higher
drive
pressur
nonunivers
hospit
time
studi
interestingli
find
corrobor
noah
et
al
wherein
transfer
ecmo
center
even
patient
cannul
ecmo
confer
surviv
benefit
adult
ard
compar
match
nonecmo
refer
patient
observ
data
point
toward
clear
reason
improv
surviv
suggest
differ
routin
support
care
patient
risk
ard
develop
affect
progress
diseas
coupl
acknowledg
best
chanc
complet
recoveri
rest
earlier
initi
appropri
therapi
studi
indic
need
identifi
patient
earlier
timepoint
cours
affect
next
type
research
research
like
enrol
patient
locat
pediatr
intens
care
unit
includ
emerg
depart
oper
room
acut
care
hospit
ward
mission
nation
institut
petal
network
prevent
earli
treatment
acut
lung
injuri
http
petalnetorg
includ
partner
icu
ed
earlier
diagnosi
initi
support
measur
pediatr
palicc
yield
intern
accept
comprehens
definit
pard
patient
risk
pard
patient
complex
comorbid
previous
oft
exclud
pardsrel
research
chronic
lung
diseas
congenit
heart
diseas
popul
atrisk
group
defin
patient
either
noninvas
posit
pressur
via
nasal
interfac
patient
nasal
cannula
either
via
tradit
heat
high
flow
nasal
cannula
specifi
oxygen
deficit
wake
establish
pediatricspecif
definit
pardi
investig
recent
complet
intern
observ
studi
pard
risk
pard
patient
initi
result
publish
tradit
pard
cohort
result
relat
atrisk
popul
includ
data
potenti
modifi
aspect
care
soon
forthcom
case
report
case
seri
describ
develop
ard
follow
episod
caus
local
system
inflamm
includ
pulmonari
air
embolu
fat
embol
still
diseas
malaria
neurogen
pulmonari
edema
describ
set
sever
neurolog
injuri
potenti
relat
larg
sympathet
surg
follow
injuri
clearli
pathophysiolog
process
inflamm
vascular
endotheli
injuri
alveolar
epitheli
injuri
fibrosi
hypercoagul
may
trigger
initi
well
patient
admit
intens
care
unit
biomark
studi
children
adult
identifi
evid
lung
injuri
even
earliest
day
hypoxemia
case
invas
mechan
ventil
initi
sever
research
observ
elev
marker
vascular
endotheli
injuri
onset
pard
diagnosi
flori
colleagu
found
highest
level
von
willebrand
factor
antigen
measur
earli
cours
pard
yehya
et
al
report
similar
find
vascular
endotheli
injuri
marker
marker
specif
alveolar
epitheli
injuri
difficult
measur
plasma
flori
colleagu
found
earli
elev
solubl
intercellular
adhes
also
marker
macrophag
activ
yehya
observ
elev
level
solubl
receptor
advanc
glycat
end
product
srage
pard
diagnosi
sapru
colleagu
identifi
earli
activ
multipl
marker
inflammatori
coagul
cascad
zinter
et
al
observ
earli
evid
matrix
metalloproteinas
releas
plasma
indic
earlyonset
fibrosi
pard
onset
final
pathogenesi
ard
felt
mediat
pathogenassoci
molecular
pattern
pamp
damageassoci
molecular
pattern
damp
biomolecul
perpetu
inflammatori
respons
circul
nucleosom
releas
cellular
injuri
bloodstream
act
damp
contribut
sever
ard
yehya
et
al
measur
circul
nucleosom
children
pard
found
strike
independ
associ
mortal
nonpulmonari
organ
failur
sever
oxygen
defect
studi
includ
pard
patient
invas
mechan
ventil
also
patient
meet
pard
criteria
noninvas
ventil
suggest
pathophysiolog
identifi
bit
earlier
cascad
studi
reflect
biomark
associ
pard
onset
describ
previous
next
phase
research
must
strive
identifi
atrisk
patient
develop
pard
identif
risk
factor
develop
may
help
clinician
bedsid
adjust
monitor
andor
initi
lung
protect
manag
strategi
earlier
patient
cours
order
prevent
pard
develop
entir
similarli
better
identif
patient
risk
pard
develop
may
enabl
research
develop
novel
therapi
initi
earlier
patient
cours
like
use
noninvas
modal
ie
inhal
treatment
altern
mode
noninvas
respiratori
support
restor
trial
sedat
manag
pediatr
acut
respiratori
failur
enrol
pediatr
patient
acut
respiratori
failur
requir
invas
mechan
ventil
secondari
primari
pulmonari
airway
diseas
patient
acut
respiratori
failur
secondari
trauma
surgeri
exclud
nonetheless
restor
studi
allow
potenti
identif
children
acut
respiratori
failur
yet
prior
pard
onset
genet
variat
biomark
children
acut
lung
injuri
bali
prospect
ancillari
studi
multisit
clinic
trial
random
evalu
sedat
titrat
respiratori
failur
restor
bali
design
examin
associ
specif
plasma
protein
genet
biomark
pard
among
prospect
enrol
children
acut
respiratori
failur
twentytwo
picu
particip
restor
volunt
particip
studi
total
patient
n
met
criteria
pard
children
n
pard
met
criteria
day
intub
studi
day
anoth
n
met
criteria
studi
day
remain
met
criteria
studi
day
level
plasma
significantli
greater
intub
day
pard
compar
without
pard
p
addit
multivari
regress
analysi
data
across
day
demonstr
signific
associ
ci
p
day
p
presenc
pard
independ
age
prismiii
addit
data
bali
relat
marker
inflamm
plasma
surfact
protein
measur
marker
dysregul
coagul
forthcom
despit
work
although
restor
enrol
patient
acut
respiratori
failur
approxim
patient
meet
pard
criteria
within
first
day
restor
enrol
therebi
limit
opportun
find
biomark
measur
prior
pard
onset
within
time
frame
allow
clinician
use
marker
measur
initi
prevent
therapi
data
corrobor
nice
adult
data
lung
safe
studi
wherein
adult
eventu
develop
ard
day
acut
hypoxem
respiratori
failur
date
pharmacolog
treatment
conclus
proven
effect
decreas
mortal
morbid
adult
children
ard
failur
pharmacolog
treatment
test
thu
far
recent
attribut
part
heterogen
patient
ard
dr
iwashyna
colleagu
develop
simul
model
demonstr
heterogen
cohort
patient
acut
respiratori
failur
significantli
impact
clinic
trial
result
show
benefit
entir
cohort
result
neg
trial
although
highrisk
subgroup
subphenotyp
patient
may
actual
benefit
treatment
b
show
benefit
entir
cohort
result
posit
trial
though
subgroup
subphenotyp
patient
may
incur
harm
treatment
recent
consensu
field
strategi
aim
prognost
identifi
highrisk
patient
predict
select
patient
like
respond
treatment
base
differ
underli
patholog
enrich
use
studi
ard
patient
identifi
target
therapi
higher
likelihood
reduc
morbid
mortal
recent
dr
calfe
delucci
use
latent
class
analysi
lca
identifi
two
novel
subphenotyp
adult
ard
patient
differ
biomark
profil
clinic
biolog
characterist
clinic
outcom
respons
treatment
team
sinc
independ
replic
two
ard
subphenotyp
use
data
addit
nhlbifund
adult
ard
trial
tabl
hyperinflammatori
ard
subphenotyp
character
part
higher
plasma
inflammatori
biomark
solubl
tumor
necrosi
factor
plasminogen
activ
receptor
advanc
glycat
end
product
rage
decreas
protein
c
associ
higher
mortal
approxim
longer
length
mechan
ventil
mv
hyperinflammatori
patient
may
preferenti
benefit
higher
peep
restrict
fluid
strategi
two
subphenotyp
appear
stabl
least
day
meet
ard
criteria
studi
identifi
pard
subphenotyp
children
primarili
recent
larg
cohort
children
pard
assuredli
next
come
patient
popul
